Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

NCT00869323 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Funding unavailable

Conditions

Lymphoproliferative Disorder

Interventions

BIOLOGICAL: rituximab
DRUG: bortezomib

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]